Thomas Hong, MD
Internal Medicine · Derry, NHNPI 1437253150
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Biosense Webster, Inc. at 54.0% of the total. 2025 is the largest year on record at $663, 4.7 times the $140 reported in 2019. Among internal medicine clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biosense Webster, Inc.$569
- AbbVie$199
- Pfizer$62
- Lilly USA, LLC$43
- Boehringer Ingelheim$42
- Novo Nordisk$37
- plus $102 from 5 others
What the payments were for
- Food & beverage$1,053100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biosense Webster, Inc. | 26 | $569 |
| AbbVie | 9 | $199 |
| Pfizer | 3 | $62 |
| Lilly USA, LLC | 3 | $43 |
| Boehringer Ingelheim | 2 | $42 |
| Novo Nordisk | 2 | $37 |
| GSK | 1 | $25 |
| Gilead | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Merck | 1 | $15 |
How this compares
$1,053 in reported general payments places this provider in the 90th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 117 | $102,290 |
| XareltoRivaroxaban | 14 | $24,883 |
| JardianceEmpagliflozin | 22 | $23,466 |
| OzempicSemaglutide | 13 | $17,927 |
| Bydureon BciseExenatide Microspheres | 11 | $9,658 |
| Atorvastatin Calcium | 696 | $6,432 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,081 |
| Metoprolol Succinate | 243 | $3,537 |
| Omeprazole | 191 | $3,305 |
| Levothyroxine Sodium | 289 | $2,972 |
| Striverdi RespimatOlodaterol Hcl | 11 | $2,958 |
| Gabapentin | 87 | $2,707 |
| Amlodipine Besylate | 460 | $2,701 |
| Lisinopril | 451 | $2,532 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $62 | $102,290117 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Striverdi Respimat | $42 | $32,50645 claims |
| Novo NordiskOzempic | $37 | $17,92713 claims |
| AbbVieSynthroid | $199 | $1,51558 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 504 internal medicine providers in New Hampshire.
Other internal medicine in Derry
- Paul MacdonaldDerry$1K
- Donald RainoneLondonderry$1.9M
- Brian HyettPortsmouth$185K
- Deborah TepperLebanon$133K
- Mark HenschkeNewington$114K
- William MonacoLebanon$97K
- Kevin PhoNashua$40K
- Mary McGowanLebanon$26K
- Magued Rizkalla HannaPortsmouth$26K
- Daniel FeldmanLebanon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.